Cabaletta's latest SEC deck pitches one CAR-T across five autoimmune diseases, with myositis first

Cabaletta Bio has put its commercial story in front of investors again. A corporate presentation dated 9 November 2026 was lodged with the US Securities and Exchange Commission. It frames the company's value around one asset: rese-cel, a CAR-T cell therapy aimed at autoimmune disease.

The deck names five target conditions: myositis, systemic lupus erythematosus, systemic sclerosis, myasthenia gravis and pemphigus vulgaris. Myositis is the one tied to a regulatory plan. The presentation refers to an intended biologics licence application, the filing a sponsor makes to seek US approval for a biological product, and to discussions with regulators.

Beyond that, the available text is thin. Much of it is standard forward-looking-statement language. It gives no submission date, no clinical results, and no account of what regulators have said, so the commercial weight of the myositis plan cannot be judged from this excerpt alone.

The presentation also links the programme to manufacturing with Cellares and mentions commercialisation plans. No technical, capacity, cost or contract terms appear in the text available, and there is nothing on pricing, launch timing or reimbursement.